PCM
SABS icon

Penserra Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Penserra Capital Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-641
Closed -$9K – 1180
2022
Q2 		$9K Buy
641
+269
+72% +$5.65K ﹤0.01% 1285
2022
Q1 		$14K Buy
372
+23
+7% +$1.06K ﹤0.01% 1352
2021
Q4 		$27K Buy
+349
New +$32.7K ﹤0.01% 1184

Other funds holding SABS

FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Penserra Capital Management's SABS Position: Q3 2022 in Review

Penserra Capital Management sold out of SAB Biotherapeutics (SABS) in Q3 2022, closing a stake of 641 shares — an estimated $9K sold.

Penserra Capital Management first reported a position in SABS in Q4 2021 and held it in 3 quarters. The position peaked at $27K in Q4 2021. 40 funds tracked by Wall St. Rank hold SABS as of Q3 2022.

  • Penserra Capital Management reported no remaining SAB Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 641 SAB Biotherapeutics shares in Q3 2022, an estimated $9K.
  • Penserra Capital Management first reported a position in SAB Biotherapeutics in Q4 2021 and held it in 3 quarters.
  • Penserra Capital Management's SAB Biotherapeutics position peaked at $27K in Q4 2021.
  • 40 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.